Development of BMS 986094 (BMS/Inhibitex) for Hepatitis C halted

BMS/Inhibitex have discontinued development of BMS 986094, for Hepatitis C, following the death of a participant in a Phase II trial. A spokesperson stated that the decision "was made in the interest of patient safety, based on a rapid, thorough and ongoing assessment of patients". The trial was voluntarily suspended on 1 August 2012. The company states that while "the cause of these unexpected events, which involve heart and kidney toxicity, has not been definitively established�it is in the best interest of patients to halt development of BMS 986094".